These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 12732878

  • 1. 'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning.
    Porter DL, Stadtmauer EA, Lazarus HM.
    Bone Marrow Transplant; 2003 May; 31(9):739-46. PubMed ID: 12732878
    [Abstract] [Full Text] [Related]

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 3. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE.
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [Abstract] [Full Text] [Related]

  • 4. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
    Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M, García-Conde J, Sanz G, Arranz R, Bernal MT, de la Serna J, Díez JL, Moraleda JM, Rubió-Félix D, Xicoy B, Martínez C, Mateos MV, Sierra J.
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
    [Abstract] [Full Text] [Related]

  • 5. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion.
    Todisco E, Castagna L, Sarina B, Mazza R, Anastasia A, Balzarotti M, Banna G, Tirelli U, Soligo D, Santoro A.
    Eur J Haematol; 2007 Apr; 78(4):322-9. PubMed ID: 17253967
    [Abstract] [Full Text] [Related]

  • 6. Allogeneic transplantation for Hodgkin's lymphoma.
    Corradini P, Sarina B, Farina L.
    Br J Haematol; 2011 Feb; 152(3):261-72. PubMed ID: 21155760
    [Abstract] [Full Text] [Related]

  • 7. Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma.
    Claviez A, Sureda A, Schmitz N.
    Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S16-24. PubMed ID: 18978738
    [Abstract] [Full Text] [Related]

  • 8. Allogeneic stem cell transplantation for the non-Hodgkin's lymphomas and Hodgkin's disease.
    Hale GA, Phillips GL.
    Cancer Treat Rev; 2000 Dec; 26(6):411-27. PubMed ID: 11139372
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D, Hunter AE, Kanz L, Slavin S, Cornelissen JJ, Gramatzki M, Niederwieser D, Russell NH, Schmitz N.
    J Clin Oncol; 2008 Jan 20; 26(3):455-62. PubMed ID: 18086796
    [Abstract] [Full Text] [Related]

  • 11. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response.
    Anderlini P, Acholonu SA, Okoroji GJ, Andersson BS, Couriel DR, De Lima MJ, Donato ML, Khouri IF, Giralt SA, Ueno NT, Champlin RE.
    Bone Marrow Transplant; 2004 Sep 20; 34(6):511-4. PubMed ID: 15273710
    [Abstract] [Full Text] [Related]

  • 12. High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma.
    Buser AS, Heim D, Bucher C, Tichelli A, Gratwohl A, Passweg JR.
    Bone Marrow Transplant; 2004 May 20; 33(10):1011-4. PubMed ID: 15064693
    [Abstract] [Full Text] [Related]

  • 13. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.
    Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, Narni F, Patriarca F, Boccadoro M, Benedetti F, Rambaldi A, Gianni AM, Tarella C.
    J Clin Oncol; 2004 Jun 01; 22(11):2172-6. PubMed ID: 15169805
    [Abstract] [Full Text] [Related]

  • 14. Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).
    Nachbaur D, Greinix HT, Koller E, Krieger O, Linkesch W, Kasparu H, Pober M, Hinterberger W, Hausmaninger H, Heistinger M, Ulsperger E, Karlhuber S, Schwinger W, Lindner B.
    Ann Hematol; 2005 Jul 01; 84(7):462-73. PubMed ID: 15726362
    [Abstract] [Full Text] [Related]

  • 15. Therapy of relapsed Hodgkin lymphoma.
    Cashen AF, Bartlett NL.
    Blood Rev; 2007 Sep 01; 21(5):233-43. PubMed ID: 17683834
    [Abstract] [Full Text] [Related]

  • 16. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen.
    Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin RE.
    Bone Marrow Transplant; 2005 May 01; 35(10):943-51. PubMed ID: 15806128
    [Abstract] [Full Text] [Related]

  • 17. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma.
    Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D, Khouri IF, Gajewski J, Claxton D, Giralt S, Rodriguez M, Romaguera J, Hagemeister F, Ha C, Cox J, Cabanillas F, Andersson BS, Champlin RE.
    Bone Marrow Transplant; 2004 May 01; 33(10):1015-23. PubMed ID: 15048145
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma.
    Seropian S, Bahceci E, Cooper DL.
    Bone Marrow Transplant; 2003 Oct 01; 32(8):763-9. PubMed ID: 14520419
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.